News

Yahoo Finance4mon
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or ...
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...
Nasdaq3y
AstraZeneca's Enhertu shows promise for broader breast cancer use
AstraZeneca said on Monday its cancer drug Enhertu helped patients with a type of advanced breast cancer live longer without their condition worsening versus chemotherapy, potentially widening the ...
Yahoo Finance2mon
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine ...
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...
Nasdaq2y
AZN: Enhertu Continues To Show Meaningful Tumor Response In Lung Cancer Across Phase II Trial
(RTTNews) - AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful tumor responses in previously-treated patients with HER2 ...
Seeking Alpha4mon
AstraZeneca's Enhertu gets additional FDA approval
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of ...
Business Insider1y
AZN : Enhertu Shows Survival Across Multiple HER2-Expressing Advanced Solid Tumors In Phase II Trial
(RTTNews) - Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically ...